BIOFLOW-III UK Satellite Registry Orsiro Stent System
Unknown statusNCT02257710
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES). 500 subjects will be enrolled in this registry.
Study details
- Official title
- BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III United Kingdom Satellite
- Conditions
- Coronary Artery Diseases
- Interventions
- Device: Orsiro
- Sponsor
- Biotronik UK Ltd.
- Start date
- 2015-11
- Primary completion
- 2018-12
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- United Kingdom
- Total sites listed
- 4
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Symptomatic coronary artery disease * Subject signed informed consent for data release * Subject is geographically stable and willing to participate at all follow up assessments * Subject is ≥ 18 years of age Exclusion Criteria: * Subject did not sign informed consent for data release * Pregnancy * Known intolerance to aspirin, clopidogrel, Ticlopidine, heparin or any other anticoagulant/antiplatelet therapy required for PCI, stainless steel, Sirolimus or contrast media * Planned surgery within 6 months after PCI unless dual antiplatelet therapy will be maintained * Currently participating in another study and primary endpoint not reached yet
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02257710